Get the Stockscreener App
2.15
4.02%
-0.09
Pre-market:
2.27
0.12
+5.58%
Maxcyte Inc stock is traded at $2.15, with a volume of 831.30K.
It is down -4.02% in the last 24 hours and down -6.52% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.24
Open:
$2.21
24h Volume:
831.30K
Relative Volume:
0.94
Market Cap:
$245.60M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.3235
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
-6.93%
1M Performance:
-6.52%
6M Performance:
-49.65%
1Y Performance:
-54.16%
1-Day Range:
$2.15
$2.256
1-Week Range:
$2.15
$2.355
52-Week Range:
$2.10
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.15 | 245.60M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing - Investing.com Australia
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - The Manila Times
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency - Nasdaq
MaxCyte and Ori Biotech Join Forces to Transform CAR-T Cell Production Timeline and Efficiency - Stock Titan
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing - TipRanks
Kalkine: NASDAQ Today Sees Movement in MaxCyte Amid Sector-Wide Shifts - Kalkine Media
Squarepoint Ops LLC Decreases Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Two Sigma Advisers LP Purchases Shares of 17,800 MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Rating Increased to Hold at Wall Street Zen - Defense World
MaxCyte Announces Change in Voting Rights Structure - TipRanks
BlackRock Increases Stake in MaxCyte to 9.98% - TipRanks
Nuveen Asset Management LLC Cuts Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
ProShare Advisors LLC Has $143,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BNP Paribas Financial Markets Takes $56,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BlackRock Increases Stake in MaxCyte - TipRanks
MaxCyte Expands Stock Capital Amidst Strategic Growth - TipRanks
Jane Street Group LLC Purchases 12,209 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Deutsche Bank AG Buys 38,782 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
D. E. Shaw & Co. Inc. Buys 84,105 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte to 7.65% - TipRanks
Price T Rowe Associates Inc. MD Has $177,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
MaxCyte, Inc. (MXCT): A Bull Case Theory - MSN
MaxCyte Inc (MXCT): Be Patient, You Will Learn - Stocksregister
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript - Insider Monkey
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities - TipRanks
William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT) - Defense World
Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Files Form 10-Q for Q1 2025 - TipRanks
BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
Earnings call transcript: MaxCyte Q1 2025 beats revenue forecast, stock reacts - Investing.com
Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times
MaxCyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):